Canaccord Genuity Starts Harpoon Therapeutics (HARP) at Buy

Go back to Canaccord Genuity Starts Harpoon Therapeutics (HARP) at Buy

Wedbush Starts Harpoon Therapeutics (HARP) at Outperform

March 5, 2019 6:45 AM EST

Wedbush analyst Robert Driscoll initiates coverage on Harpoon Therapeutics (NASDAQ: HARP) with a Outperform rating and a price target of $23.00.

For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.

Shares of Harpoon Therapeutics closed at $17.01 yesterday.

... More